Table 1 Patient characteristics and clinicopathological variables of the study cohorts
From: Molecular analyses of triple-negative breast cancer in the young and elderly
All patients | Patients < 40 years | Patients 40–50 years | Patients 50–60 years | Patients 60–70 years | Patients 70–80 years | Patients ≥ 80 years | Statistical difference between age groupsE | |
|---|---|---|---|---|---|---|---|---|
N | 237 | 28 | 24 | 55 | 53 | 40 | 37 | |
ER IHC % (1–10%) A | 12.3% | 10.7% | 16.7% | 9.3% | 15.1% | 10.3% | 13.5% | p = 1.0 |
Tumor size > 20 mm | 49.4% | 46.4% | 37.5% | 40.0% | 50.9% | 42.5% | 78.4% | p = 0.09 |
Grade 3 (%) | 87.9% | 96.3% | 100% | 94.3% | 78.4% | 80% | 86.5% | p = 0.29 |
Median Ki67% | 70 | 87 | 78 | 70 | 70 | 58 | 60 | |
Node positive (%) | 34.6% | 37.0% | 29.2% | 32.1% | 34.0% | 37.5% | 37.8% | p = 1.0 |
Adjuvant chemotherapy (%) | 72.8% | 100% | 100% | 94.5% | 84.9% | 59.0% | 0% | p = 4e−15 |
Outcome | ||||||||
Death events (%) | 26.6% | 17.9% | 0% | 12.7% | 32.1% | 27.5% | 62.2% | p = 3e−6 |
IDFS events (%) | 32.5% | 25.0% | 12.5% | 16.4% | 39.6% | 35.0% | 62.2% | p = 0.0007 |
Distant metastases (%) | 20.7% | 21.4% | 8.3% | 14.5% | 28.3% | 20.0% | 27.0% | p = 1.0 |
BRCA1-germline (%) B | 8.0% | 28.6% | 4.2% | 12.7% | 1.9% | 5.0% | 0% | p = 0.003 |
BRCA1 status | ||||||||
BRCA1-null C (%) | 10.5% | 32.1% | 4.2% | 16.4% | 7.5% | 5.0% | 0% | p = 0.006 |
BRCA1 hypermethylation (%) | 24.1% | 50.0% | 41.7% | 21.8% | 28.3% | 10.0% | 5.4% | p = 0.001 |
BRCA1 wildtype D | 65.4% | 17.9% | 54.1% | 61.8% | 64.2% | 85% | 94.6% | p = 2e−8 |
HRD status | p = 1e−6 | |||||||
HRDetect-high (%) | 58.6% | 92.9% | 83.3′% | 67.3% | 60.4% | 27.5% | 35.1% | |
HRDetect-intermediate (%) | 5.5% | 0% | 4.2% | 5.5% | 1.9% | 5.0% | 16.2% | |
HRDetect-low (%) | 35.9% | 7.1% | 12.5% | 27.3% | 37.7% | 67.5% | 48.6% | |
PD-L1 positivity (%) | 51.8% | 65.4% | 54.5% | 62.7% | 46.0% | 40.0% | 44.1% | p = 1.0 |
TILs (%) | p = 1.0 | |||||||
< 30% | 61.5% | 46.2% | 40.9% | 51.0% | 73.5% | 76.5% | 69.7% | |
30–50% | 17.8% | 19.2% | 31.8% | 24.5% | 10.2% | 11.8% | 15.2% | |
> 50% | 20.7% | 34.6% | 27.3% | 24.5% | 16.3% | 11.8% | 15.2% | |
PAM50 subtypes (%) | p = 0.001 | |||||||
Basal-like | 79.9% | 100% | 95.7% | 94.3% | 73.5% | 57.1% | 63.9% | |
HER2-enriched | 14.7% | 0% | 4.3% | 1.9% | 16.3% | 28.6% | 36.1% | |
Luminal A | 1.3% | 0% | 0% | 0% | 2.0% | 5.7% | 0% | |
Luminal B | 0.4% | 0% | 0% | 0% | 0% | 2.9% | 0% | |
Normal-like | 3.6% | 0% | 0% | 3.8% | 8.2% | 5.7% | 0% | |
TNBC subtypes (%) | p = 0.22 | |||||||
BL1 | 20.2% | 14.3% | 26.1% | 26.4% | 20.4% | 14.7% | 16.7% | |
BL2 | 9.9% | 10.7% | 8.7% | 11.3% | 10.2% | 5.9% | 11.1% | |
IM | 20.2% | 25.0% | 21.7% | 28.3% | 14.3% | 17.6% | 13.9% | |
LAR | 13.0% | 0% | 0% | 3.8% | 16.3% | 23.5% | 30.6% | |
M | 18.4% | 17.9% | 21.7% | 18.9% | 20.4% | 8.8% | 22.2% | |
MSL | 6.3% | 7.1% | 13.0% | 1.9% | 4.1% | 17.6% | 0% | |
UNS | 12.1% | 25.0% | 8.7% | 9.4% | 14.3% | 11.8% | 5.6% | |
IntClust10 subtypes | p = 0.07 | |||||||
1 | 0.9% | 0% | 4.3% | 0% | 0% | 0% | 2.8% | |
10 | 64.7% | 89.3% | 87.0% | 79.2% | 57.1% | 40.0% | 44.4% | |
3 | 2.2% | 0% | 4.3% | 1.9% | 2.0% | 5.7% | 0% | |
4 | 25.0% | 3.6% | 4.3% | 17.0% | 30.6% | 40.0% | 44.4% | |
5 | 0.9% | 0% | 0% | 0% | 2.0% | 2.9% | 0% | |
8 | 0.4% | 0% | 0% | 0% | 0% | 2.9% | 0% | |
9 | 5.8% | 7.1.% | 0% | 1.9% | 8.2% | 8.6% | 8.3% | |